Press communication
Lund, Sweden, February 14

This is a translation of the Swedish press release published 2024-02-14, 08.00 CET

Neola Medical AB (publ) today publishes the Q4 report of 2023 (in Swedish). The report is available at the company’s website and is attached to the press release.

During the quarter, Neola Medical laid the foundation for the upcoming commercial launch of its medical technology for lung monitoring by establishing a subsidiary in the USA. With a new strategic patent for the company’s disposables, significant protection is also provided for a substantial part of the company’s future profitability model. The quarter concluded with another strong statement following the completion of a directed new share issue at a premium to the share price, securing capital for 2024 and the clinical study in the USA conducted ahead of the forthcoming FDA application. During the year, the largest clinical study to date with 100 newborns has been completed, and successful new results show that Neola® measures lung oxygen in 100% of the participating newborns and that the company’s GASMAS technology is a safe, stable, and well-tolerated technology for monitoring the lungs of preterm born infants. In preparation for the forthcoming FDA application, the company has established a close collaboration with Stanford and has been designated as a Stanford Impact1 company with the opportunity to make a difference in healthcare from day 1.

Read the entire press release (in Swedish) here: Neola Medical Bokslutskommuniké 2023 – Med stärkt kassa levereras ännu ett styrkebesked genom patentskydd för kommande lönsamhetsdrivare

For further information, contact:
Hanna Sjöström, CEO Neola Medical, phone: +46 (0)760-10 71 16, e-mail:

Neola Medical AB (publ) develops medical technology device for continuous monitoring of preterm born infants’ lungs. Immediate detection of complications provides the possibility of early treatment and improved health care. The patented technology is based on a spectroscopic method developed at Lund University in Sweden. The company was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at The company’s Certified Adviser is FNCA Sweden AB.

This information is the type of information that Neola Medical is required to disclose according to the EU Market Abuse Regulation. The information was provided, through the agency of the above-mentioned contact person, for publication on 2024-02-14 08:00 CET.